Autus Valve Continued Access Study (CAS)

Recruiting now · Not applicable

Conditions studied: Congenital Heart Disease

In brief

Prospective, single-arm, multi-center, continued access study of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implantation, at hospital discharge, 30 days, 6 months, and annually through 10 years. The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject.

Key facts

Study ID

NCT07466745

Run by

Edwards Lifesciences

People needed

36

Starts

2026-07-27

Expected to finish

2036-04-30

Last updated by the study team

2026-08-10

Who can join

Age: 2 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 months to 16 years.
• Male or female.
• Subject has a native or repaired right ventricular outflow tract.
• Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).
• Subject has at least one of the following echocardiographic findings:
• Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg);
• Moderate or greater pulmonary regurgitation;
• Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.
• Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).
• Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.
• Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.

You may not qualify if…

• Subject requires valve replacement in a non-pulmonary position.
• Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).
• Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).
• Subject has a known history of pulmonary atresia and major aortopulmonary collaterals.
• Subject has significant peripheral pulmonary artery stenosis.
• Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
• Subject has active endocarditis or a history of infective endocarditis.
• Subject has a known history of renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.
• Subject has a known history of leukopenia (defined as a white blood cell [WBC] count <3.5 x 103/µL).
• Subject has a known history of acute or chronic anemia (defined as hemoglobin [Hgb] <10.0 g/dl or 6 mmol/L).
• Subject has a known history of thrombocytopenia (defined as platelet count <50 x 103/µL).
• Subject has a known history of hypersensitivity to anticoagulants and antiplatelet drugs.
• Subject has a known history of autoimmune disease or receives immunosuppressant and/or immunostimulant drugs, and the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.
• Subject needs emergency cardiac or vascular surgery or intervention.
• Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.
• Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.
• Subject or parent/legal representative refuses blood transfusions.
• Subject has medical, social, or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.
• Subject is participating in an investigational study of a new drug, biologic, or device at the time of study screening.

Where it is running

• University of Michigan - Mott Children's Hospital — Ann Arbor, Michigan, United States (enrolling)
• Children's Hospital Colorado — Aurora, Colorado, United States
• Children's Healthcare of Atlanta — Atlanta, Georgia, United States
• Boston Children's Hospital — Boston, Massachusetts, United States
• Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital — New York, New York, United States
• Duke University — Durham, North Carolina, United States
• Nationwide Children's Hospital — Columbus, Ohio, United States
• University of Utah - Intermountain Primary Children's Hospital — Salt Lake City, Utah, United States
• Children's Hospital Los Angeles — Los Angeles, California, United States
• Seattle Children's Hospital — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.